MedTrace Logo

Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus

NCT00003054 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2018-04-12

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

PURPOSE: Phase II trial to study the effectiveness of paclitaxel in treating patients with recurrent or persistent cancer of the uterus.

Conditions

  • Sarcoma

Interventions

DRUG

paclitaxel

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Gynecologic Oncology Group

    lead NETWORK

Principal Investigators

  • Donald G. Gallup, MD · Curtis and Elizabeth Anderson Cancer Institute at Memorial Health University Medical Center

Study Design

Purpose
TREATMENT

Eligibility

Max Age
120 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
1997-08-31
Primary Completion
2002-07-31

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00003054 on ClinicalTrials.gov